Ghodratollah Roshanaei - Modeling of Noncommunicable Diseases Research Center, Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Farshad Rostampour - Student Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
Mohammadreza Javadi - Department of General Surgery, Faculty of Medicine, Hamadan University of Medical Sciences and Health Services, Hamadan, Iran
Sepideh Behnoud - Department of General Surgery, Faculty of Medicine, Hamadan University of Medical Sciences and Health Services, Hamadan, Iran
Masoud Sabouri Ghannad - Research Center for Molecular Medicine, Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Background: Gastric cancer is the second leading cause of cancer death. The aim of this study was to determine the survival rate affected by risk factors in patients with gastric adenocarcinoma.Methods: We performed this retrospective cohort study on patients diagnosed with gastric adenocarcinoma during ۲۰۰۵-۲۰۱۲ in Hamadan, Iran. All patients with pathological diagnosis enrolled in the study. The effects of patients’ demographical and pathological data were assessed in terms of survival. The univariate and multivariate Weibull models were used to determine the effects of these factors on survival rate. Data was analyzed by SPSS۱۶ and STATA۱۰ software.Results: A total of ۱۱۲ gastric adenocarcinoma patients were followed. Patients included ۷۴ (۶۶.۱%) males. During the follow-up, ۱۰۲ (۹۱.۱) patients died. Patients’ had a mean (SD) survival of ۲۱.۹ (۱.۹) months and a median survival of ۱۵ months. The “one-, three- and five-year survival rates were ۶۲%, ۱۶% and ۹% respectively. The results showed that metastasis, chemotherapy, tumor site and grade had statistically significant impacts on patient survival.Conclusion: A potentially important role for tumor grade, tumor site, metastasis, and pathologic stage of disease existed in terms of patient survival after surgery. The current research has indicated that neoadjuvant treatment increased survival in patients with gastric adenocarcinoma. It is expected that the prognostic model based on the mentioned factors may assist individual risk stratification and help in the planning of potential forthcoming studies.